Unconfigured Ad

Collapse
X
 
  • Filter
  • Time
  • Show
Clear All
new posts
  • Simon Anders
    Senior Member
    • Feb 2010
    • 995

    #16
    By the way: The effect of seeing a large count for a gene in one sample and zero counts in all other samples is quite common when working with sample derived from very few cells.

    In such cases, it is not too uncommon that one only gets maybe around a million mRNA molecules per sample, and after reverse transcription, this is down to possibly less than a hundred thousand cDNA molecules, which then go through many rounds of PCR. If one then sequences this to a depth of a few million reads per sample, i.e., much more reads than there were initial cDNA molecules, then one is bound to see most transcript molecules several times and some individual cDNA molecules, which fared especially well in the PCR, can easily produce hundreds of reads, all showing fragments of the very same mRNA molecule.

    Hence, in a setting with very low amounts of starting RNA (typically, below ~1 µg of total RNA per sample), it is quite possible to see a huge difference, say hundreds of reads in one sample and zero reads for the same gene in all other samples, and in reality, this reflects a difference of only a single lone mRNA molecule.

    See also our paper on this issue:
    Brenencke, Anders, Kim et al., Accounting for technical noise in single-cell RNA-seq experiments
    Nature Methods, 10, 1093–1095 (2013)
    doi:10.1038/nmeth.2645
    Last edited by Simon Anders; 05-23-2014, 04:15 AM.

    Comment

    Latest Articles

    Collapse

    • SEQadmin2
      Cancer Drug Resistance: The Lingering Barrier to Rising Survival
      by SEQadmin2



      Cancer survival rates have significantly increased in the last few decades in the United States, reaching a combined 70% 5-year survival rate by 2021. Behind this number, there are years of research to find new therapies, drug targets, and early detection methods. But there is one core challenge that keeps slowing down these advances, and it’s about drug resistance.

      There is no single reason why many patients don’t respond to treatment as expected. Cancer is...
      Today, 05:17 AM
    • GATTACAT
      Reply to Nine Things a Sample Prep Scientist Thinks About Before Sequencing
      by GATTACAT
      Love this - good data definitely starts from good input, and poor input can only give relatively poor data. I particularly like the mention of Nanodrop/absorbance based methods for quantification. It's such a toss up if you'll get an accurate reading or what amounts to a randomly generated number, and a lot of library/sequencing related issues can be traced back to poor quant.
      07-01-2026, 11:43 AM
    • SEQadmin2
      Nine Things a Sample Prep Scientist Thinks About Before Sequencing
      by SEQadmin2


      I’m not a sequencing expert. I’m a purification scientist who uses NGS to evaluate workflows my group develops. With this perspective, we think about the sample first and the NGS workflow second. The sequencer is an exceptionally honest reporter, but it can only report on what you give it, so whether you get clean, interpretable data from an NGS workflow is largely determined before you begin.

      Here are nine questions we think about, in roughly the order they matter, before...
      06-18-2026, 07:11 AM

    ad_right_rmr

    Collapse

    News

    Collapse

    Topics Statistics Last Post
    Started by SEQadmin2, Yesterday, 11:05 AM
    0 responses
    7 views
    0 reactions
    Last Post SEQadmin2  
    Started by SEQadmin2, 07-02-2026, 11:08 AM
    0 responses
    29 views
    0 reactions
    Last Post SEQadmin2  
    Started by SEQadmin2, 06-30-2026, 05:37 AM
    0 responses
    28 views
    0 reactions
    Last Post SEQadmin2  
    Started by SEQadmin2, 06-26-2026, 11:10 AM
    0 responses
    27 views
    0 reactions
    Last Post SEQadmin2  
    Working...